Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Darunavir/Cobicistat FDC in Healthy Japanese Adults
NCT03123848Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of darunavir and cobicistat in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time and 5 more. Started Apr 2017; status: completed.
02
Drugs
darunavircobicistat
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03123848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03123848.